Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: Results from a cross-sectional study
EntityUAM. Departamento de Medicina; Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)
PublisherWiley Periodicals, Inc. on behalf of American College of Rheumatology
10.1002/acr.23910Arthritis Care and Research 72.8 (2020): 822-828
ISSN2151-464X (print); 2151-4658 (online)
SubjectsComorbidities; Cardiovascular in Rheumatology; Ankylosing spondylitis; Psoriatic arthritis; Medicina
NoteArtículo con numerosos autores. Sólo quedan reflejados el primero, los de la UAM y el Grupo Colectivo
Rights© 2020 The Authors. Arthritis Care & Research
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
To evaluate the impact of comorbidities on physical function in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods: This was a cross-sectional analysis of the baseline visit from the Cardiovascular in Rheumatology study. Multivariate models with physical function as the dependent variable (Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire for AS and PsA, respectively) were performed. Independent variables were a proxy for the Charlson Comorbidity Index (CCIp; range 0–27), sociodemographic data, disease activity (erythrocyte sedimentation rate [ESR] and Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] in AS; Disease Activity Score in 28 joints [DAS28] using the ESR in PsA), disease duration, radiographic damage, and treatments. Results were reported as beta coefficients, 95% confidence intervals (95% CIs), and P values. Results: We included 738 patients with AS and 721 with PsA; 21% of patients had >1 comorbidity. Comorbidity burden (CCIp) was independently associated with worse adjusted physical function in patients with PsA (β = 0.11). Also, female sex (β = 0.14), disease duration (β = 0.01), disease activity (DAS28-ESR; β = 0.19), and the use of nonsteroidal antiinflammatory drugs (β = 0.09), glucocorticoids (β = 0.11), and biologics (β = 0.15) were associated with worse function in patients with PsA. A higher education level was associated with less disability (β = –0.14). In patients with AS, age (β = 0.03), disease activity (BASDAI; β = 0.81), radiographic damage (β = 0.61), and the use of biologics (β = 0.51) were independently associated with worse function on multivariate analyses, but CCIp was not. Conclusion: The presence of comorbidities in patients with PsA is independently associated with worse physical function. The detection and control of the comorbidities may yield an integral management of the disease.
Google Scholar:Fernández-Carballido, Cristina - Castañeda Sanz, Santos - García de Vicuña Pinedo, María del Rosario - Cardiovascular in Rheumatology Project Collaborative Group
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis González-Alvaro, Isidoro; Ortíz, Ana María; Álvaro-Gracia, José María; Castañeda Sanz, Santos; Díaz-Sánchez, Belén; Carvajal, Inmaculada; García Vadillo, Jesús Alberto; Humbría, Alicia; López-Bote, Juan Pedro; Patiño, Esther; Tomero, Eva G.; Vicente, Esther; Sabando, Pedro; García de Vicuña Pinedo, María del Rosario
Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients García-Bermúdez, Mercedes; González-Juanatey, Carlos; López-Mejías, Raquel; Teruel, María; Corrales, Alfonso; Miranda-Filloy, José Alberto; Castañeda Sanz, Santos; Balsa Criado, Alejandro; Fernández-Gutiérrez, Benjamín; González-Alvaro, Isidoro; Gómez-Vaquero, Carmen; Blanco, Ricardo; Llorca, Javier; Martín, Javier E.; González-Gay, Miguel Ángel